Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
635 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,688 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT02732015 | Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT02181829 | Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases | completed | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02691026 | A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery | terminated | Phase 2 | 8 | Oslo University HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04910126 | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | unknown | Phase 2 | 84 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02888665 | Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | May 26, 2021 | clinicaltrials |
| NCT04886765 | A Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma | unknown | Phase 1 / Phase 2 | 238 | AlaMab Therapeutics (Shanghai) Inc.INDUSTRY | 0 | May 14, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01759303 | Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung | terminated | Phase 2 | 12 | Emerald Clinical Inc.INDUSTRY | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02379845 | NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall | completed | Phase 2 / Phase 3 | 180 | NanobiotixINDUSTRY | 13 | Apr 6, 2021 | clinicaltrials |
| NCT01140737 | A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas(Axi-STS) | completed | Phase 2 | 145 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01276236 | Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) | completed | Phase 2 | 13 | University of California, San FranciscoOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT02448537 | A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03623581 | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) | unknown | Phase 2 | 35 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Yong ChenOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00642941 | A Study of R1507 in Participants With Recurrent or Refractory Sarcoma | terminated | Phase 2 | 317 | Hoffmann-La RocheINDUSTRY | 11 | Feb 3, 2021 | clinicaltrials |
| NCT01833520 | Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma | completed | Phase 1 / Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT03989596 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas(SINDIR) | unknown | Phase 2 | 30 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01543802 | Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma(NOPASS) | terminated | Phase 2 | 21 | Heidelberg UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial(APLIPO) | terminated | Phase 2 | 24 | Institut BergoniéOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03651375 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall(UN-RESARC) | unknown | Phase 2 | 46 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02423863 | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®(Poly-ICLC) | completed | Phase 2 | 26 | Oncovir, Inc.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03468075 | Gemcitabine Plus Ascorbate for Sarcoma in Adults | terminated | Phase 2 | 10 | Mohammed Milhem, MBBSOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04606108 | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma | unknown | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT03013127 | A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery(PROMO) | terminated | Phase 2 | 12 | Oslo University HospitalOTHER | 2 | Oct 14, 2020 | clinicaltrials |
| NCT02301039 | SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | completed | Phase 2 | 144 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01987102 | Investigation of [6R] 5,10-methylenetetrahydrofolate (Arfolitixorin) as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX. | completed | Phase 1 / Phase 2 | 18 | Isofol Medical ABINDUSTRY | 4 | Sep 25, 2020 | clinicaltrials |
| NCT00860015 | Alimta Plus Gemcitabine for Advanced Sarcoma | completed | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Aug 25, 2020 | clinicaltrials |
| NCT00880542 | Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery | terminated | Phase 2 | 7 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT02300545 | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | completed | Phase 2 | 56 | Washington University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT03509207 | Vorinostat (SAHA) in Uterine Sarcoma | terminated | Phase 2 | 3 | Medical University of GrazOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial | completed | Phase 2 | 52 | Grupo Espanol de Investigacion en SarcomasOTHER | 2 | Jul 23, 2020 | clinicaltrials |
| NCT01817530 | Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) | completed | Phase 2 | 571 | AbbVieINDUSTRY | 0 | Jul 21, 2020 | clinicaltrials |
| NCT03698227 | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | terminated | Phase 2 | 2 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04356872 | The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04447274 | A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 0 | Jun 25, 2020 | clinicaltrials |
| NCT02968303 | Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy(COWBOY) | unknown | Phase 2 | 200 | Radboud University Medical CenterOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT01975519 | A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 111 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | May 20, 2020 | clinicaltrials |
| NCT02097238 | Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 2 | May 19, 2020 | clinicaltrials |
| NCT03104335 | Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | withdrawn | Phase 2 | 0 | Peking University People's HospitalOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT04351308 | Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma(MAPAC) | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | May 19, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT03268772 | PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Sep 14, 2021source: clinicaltrials